Skip to main content

16-02-2020 | ASCO GU 2020 | Conference coverage | Video

Expert highlights from ASCO GU 2020

Axel Merseburger takes us through the studies that caught his attention at the 2020 Genitourinary Cancers Symposium (ASCO GU 2020), including the NIMBUS trial and first-in-human study of the HIF-2α inhibitor MK-6482 (3:24).

Read transcript

Related content